Amebiasis is a parasitic disease caused by the microscopic protozoan Entamoeba histolytica. Infection occurs through the ingestion of cysts from contaminated water or food. Worldwide, approximately 50 million symptomatic cases are estimated annually, mainly in tropical and subtropical regions.
Fumagillin, a fungal natural product, has been studied for decades as a potential antiparasitic drug, but its more potent relative, ovalicin, was never developed. Now, a study published in the Journal of the American Chemical Society reveals why: although ovalicin is highly active against amebiasis, liver enzymes rapidly break it down in the body. Researchers used a chem-bio hybrid approach to turn that insight into metabolically stable drug candidates that worked in animal models of amebiasis, including liver infection with abscess formation.
The research team, led by scientists from the Graduate School of Bioagricultural Sciences at Nagoya University, identified the liver cytochrome P450 enzymes responsible for ovalicin breakdown, with CYP 2B1 and CYP 2C6 emerging as the main drivers. Blocking these enzymes with a chemical inhibitor significantly prolonged ovalicin survival, providing strong evidence that rapid liver metabolism limits its effectiveness.









